Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Severfield trading as expected, flags second-half weighting

(Sharecast News) - Severfield said in an update on Tuesday that trading since the start of its financial year had been in line with expectations, with full-year results for the 2026 financial year still expected to be heavily weighted towards the second half. The London-listed structural steel specialist reported an order book of £420m for the UK and Europe as of 1 September, down from £444m in July but with £330m of work scheduled for delivery over the next 12 months.

It said 19% of the order book related to projects in continental Europe and Ireland, compared with 22% previously.

In India, Severfield's joint venture JSSL reported a record order book of £252m, up from £240m in July, with 85% comprising higher-margin commercial work.

The company said India's construction sector and use of structural steel continued to grow strongly.

Severfield said the bridge remedial works programme was progressing as planned, with no changes to cost estimates.

It confirmed it had now received the full £20m insurance recovery agreed with its professional indemnity insurers.

The company recently extended its £60m revolving credit facility to December 2027, and said its financial position remained strong with a continued focus on cash generation and working capital control.

Half-year results were due on 25 November.

At 1227 BST, Severfield shares were down 0.34% at 32.39p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.